ClinicalTrials.gg
RecruitingNCT07663942BARIMOVUpdated Jun 23, 2026

Targeting Sedentary Behavior Reduction and Physical Fitness Enhancement in Women Before and Beyond Bariatric Surgery- BARIMOV Study Protocol

An interventional study of Sedentary behavior reduction program on physical fitness. in Obesity (Disorder), sponsored by Hospital de Sao Sebastiao. Recruiting at 1 site in Portugal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Hospital de Sao Sebastiao · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Obesity with a site in Portugal — 26 open to participants now, 32 under way, 12 of them phase 3. Obesity · Portugal.

Planned enrollment
45th of 62
72 · median 150
Started
2026
with 8 others
No phase
35 of 68
14 open now
Primary completion
2030-10
later than 29 of 31 live
Registered
61st of 68
by date
Lead sponsor
2 of 68
Hospital de Sao Sebastiao

Among the 68 studies in Obesity with a site in Portugal, this one is the 45th largest by planned enrollment of the 62 interventional ones that give a count, is one of 9 that started in 2026, is one of 35 with no phase, reaches primary completion later than 29 of the 31 other live ones, and was the 61st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

26 of the 68 studies in Obesity with a site in Portugal are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Obesity with a site in Portugal, or all of them as a file.
02

Study summary

Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Replacing SB with low-intensity PA may improve PF and ameliorate ORCD, with potential lasting effects after bariatric surgery (BS). However, strong evidence on how PF influences BS outcomes and whether preoperative PA interventions can improve postoperative outcomes is lacking. The BARIMOV study aims to evaluate the effects of a structured sedentary behavior reduction program (SBRPro) on PF, investigate whether PF improvements influence BS outcomes, and explore potential mechanistic pathways by characterizing molecular adaptations in peripheral blood, skeletal muscle, and visceral adipose tissue (VAT).

Methods: BARIMOV is a prospective cohort study with five assessment time points. Adult women (≥18 years) with BMI 30-45 kg/m² scheduled for BS will be recruited (n = 72). At T0, participants will undergo a baseline assessment of PF - body composition, muscle strength, cardiorespiratory fitness - PA patterns, and ORCD screening. Participants will be instructed in the SBRPro and asked to maintain weekly PA diaries throughout the pre- and post-operative periods. At T1, adherence to SBRPro will be evaluated via diary review and PF reassessment, to enable participants' allocation into two adherence-based groups. At T2, during surgery, skeletal muscle and VAT biopsies will be collected for proteomic analysis to compare molecular adaptations of adherent and non-adherent groups. At T3 and T4, primary outcomes, including weight loss, body composition, ORCD, and quality of life (QoL), will be evaluated at 3±1 and 12±1 months postoperatively, respectively. Blood multiomics profiling will be performed at T0, T1, and T3 to explore dynamic changes in systemic metabolic pathways over time.

Conclusion: This study will determine whether PF improvement, achieved through structured SB reduction and PA engagement, is associated with better BS outcomes. By integrating clinical and molecular endpoints, the study will provide mechanistic insights into the pathways by which PF enhances BS outcomes and inform physical activity intervention strategies.

Read the detailed description
  • Study Design and Participants BARIMOV will be a prospective cohort study designed to evaluate the effects of an SBRPro on BS outcomes in women and to explore the biological mechanisms underlying these effects. The study includes five predefined assessment timepoints: baseline (T0, 6±3 months before surgery), preoperative reassessment (T1, 2 weeks±3 days before surgery), intraoperative biopsies (T2), early postoperative reassessment (T3, 3±1 months after surgery), and final postoperative reassessment (T4, 12±2 months after surgery).
  • Intervention Participants will be instructed to follow an online SBRPro program initiated 6±3 months before surgery. SBRPro provides standardized guidance on decreasing sedentary time and increasing regular PA, tailored to individual capabilities, delivered via mobile phone apps featuring messages, videos, and PA and exercise tutorials. The intervention will comprise 3 main phases.

Phase 1: Enrollment and Multidisciplinary Education (T0) All participants will attend a group educational session (40 minutes) delivered by a multidisciplinary team (bariatric surgeon, exercise physiologist, dietitian) addressing: 1) overall education about the BS clinical process and surgery procedures, risks, advantages and disadvantages; 2) a comprehensive education on SB harms and health risks, and benefits of PA across the pre- and post-operative period; 3) practical strategies for reducing sedentary time (e.g., breaking up prolonged sitting or interrupting extended bouts); 4) PA safety, proper exercise execution, PA intensity management and progression strategies; 5) nutritional education for preoperative fitness and postoperative recovery; and 6) distribution of written materials (flyers and booklets) summarizing key take home contents delivered at the session.

Phase 2: Structured Preoperative Sedentary Behavior Reduction Program (T0 to T1) Participants will be asked to engage in the SBRPro, which includes aerobic and strength activities, in compliance with current PA guidelines. Flexibility to adapt the PA and exercise modality, duration, and intensity based on individual preferences, physical capacity, and available resources (home-based, gym-based, online platforms, or combined approaches) will be provided.

Phase 3: Structured Postoperative Sedentary Behavior Reduction Program (T2 to T4) Participants will be asked to resume SBRPro activities within the first week post-BS, adjusting the program for postoperative individual restrictions. A progressive increase in daily PA will be encouraged. For resistance exercises, participants will be advised to avoid heavy loading of incision/staple lines and to progress from light to moderate resistance as tolerated. Given the postoperative vulnerability, remote counseling will be provided as needed to enhance safety. The same weekly PA diary-based monitoring will be requested.

Physical Activity Monitoring and Adherence Assessment SBRPro adherence will be assessed through a structured weekly PA diary using a simple online form. The form will collect self-reported data on average daily sedentary time (minutes per day), total time spent in light, moderate, and vigorous physical activity (minutes per week), and the number of days per week engaged in resistance training. The form will also include a subsection addressing PA satisfaction/enjoyment (5-point Likert scale: 1, nothing fun; 2, little fun; 3, indifferent; 4, fun; 5, very fun), and any barriers or adverse events encountered. This weekly assessment will take place from baseline (the moment of enrolment in the study) until up to 12 months after surgery. For primary analyses, adherence subgroups, determined from the weekly PA diary, will be classified as having either an active or a sedentary lifestyle according to the most recent World Health Organization criteria. Individuals will be classified as physically active if they accumulate at least 150 minutes of moderate-intensity physical activity per week, and as sedentary if they do not meet this threshold. Participants with a sedentary lifestyle will serve as the de facto comparison group. This will enable evaluation of whether differential engagement with the SBRPro is associated with distinct clinical and functional outcomes.

  • Clinical and Functional Assessments PF evaluations that include changes in body composition, muscle strength, and CRF will be assessed to determine the effects of the SBRPro. Body composition [total weight (kg) and weight loss (absolute and % excess weight lost), fat mass (kg and %), lean mass (kg and %), muscle mass (kg and %)] will be measured via bioimpedance analysis (InBody 970 model, Biospace, Korea). Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The estimated CRF (eVO2m) will be evaluated using the 2-minute step test (2MST). Changes in PA patterns between T0 and T1, and T2 and T3 will be subjectively measured using the language validated 24-hour movement questionnaire (QMov24h) and objectively measured PA, between T1 and T2, via accelerometry (ActiGraph wGT3X-BT model, Ametrics, USA), worn for 7 days, quantifying daily activity volume (steps, minutes of light, moderate, and vigorous activity), and sedentary time. The resolution or improvement of the ORCD and the health-related QoL will be assessed using the SF-12 (12-item Short Form Health Survey) validated questionnaire.
  • Biological Sampling and Molecular Analyses Fasting blood samples will be collected at T0, T1, and T3. Plasma will be processed and stored at -80ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points. Molecular findings will subsequently be integrated with clinical and functional outcomes to explore potential mechanistic links between behavioral modification, tissue remodeling, and postoperative results.

During BS (T2), biopsies of abdominal skeletal muscle (transversus abdominis) and visceral adipose tissue (VAT) will be obtained under direct surgical visualization. Tissue fragments will be immediately processed and preserved at -80ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups. Functional enrichment and pathway analyses will be conducted to characterize biological processes associated with preoperative SB reduction and PA engagement.

03

Conditions studied

  • Obesity (Disorder)

Keywords

  • physical inactivity
  • weight loss
  • quality of life
  • adiposity
  • skeletal muscle
  • adipose tissue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women (≥ 18 years);
  • of 30-45 kg/m2;
  • Scheduled for primary vertical sleeve gastrectomy or Roux-en-Y gastric bypass;
  • Capacity to provide , adequate proficiency in the national language;
  • Access to the internet and mobile phone communication.

Exclusion criteria

Exclusion Criteria:

  • Previous bariatric surgery or gastric surgical procedure;
  • Physical incapacity or medical precluding physical fitness testing or participation (active cardiac disease, uncontrolled hypertension, severe joint disease);
  • Pregnancy or breastfeeding;
  • Inability to provide or comply with study procedures;
  • Patients with type 1 or 2 diabetes mellitus.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Adherent group

    Participants will be instructed in the sedentary behavior reduction program (SBRPro) and asked to maintain weekly physical activity diaries throughout the pre- and post-operative periods.

    Behavioral: Sedentary behavior reduction program on physical fitness.

  • No intervention
    Non-adherent group

    Non-adherence to the sedentary behavior reduction program.

Interventions

  • BehavioralSedentary behavior reduction program on physical fitness.

    The BARIMOV protocol incorporates this evidence through a structured, online sedentary behavior reduction program (SBRPro) that emphasizes substituting sedentary behavior with physical activity throughout the day.

06

What researchers measure

Primary outcomes

  1. Percentage of total weight loss (%TWL)

    Primary clinical outcome evaluating the percentage of total weight loss, measuring weight in kilograms before and after surgery.

    Time frame: Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

  2. Obesity-related complications and diseases (ORCD)

    Pre- and post-operative status comparison through in-person clinical evaluations and routine laboratory analyses, including physical examination findings and longitudinal changes in pharmacological treatment requirements. ORCD will be assessed as a composite outcome including the presence of the following conditions, defined using a standardized criterion: Type 2 diabetes mellitus: HbA1c≥6.5% or use of glucose-lowering medication; Hypertension: systolic BP≥140 mmHg, diastolic BP≥90 mmHg, or antihypertensive treatment; Dyslipidemia: LDL-C, HDL-C, or triglycerides outside guideline thresholds or lipid-lowering therapy; Obstructive sleep apnea: confirmed by polysomnography \[AHI≥5 events/hour\]; Gastroesophageal reflux disease (GERD): heartburn and/or acid regurgitation occurring≥2 times per week or current use of proton pump inhibitors (PPIs) for reflux symptoms with prior physician diagnosis of GERD; Metabolic syndrome: defined according to NCEP ATP ΙΙΙ criteria.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

  3. Changes in health-related quality of life (QoL)

    Primary clinical outcome assessed by using the SF-12 (12-item Short Form Health Survey), a validated questionnaire.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

Secondary outcomes

  1. Body composition

    Body composition \[fat mass (in kilograms and percentage), lean mass (in kilograms and percentage), muscle mass (in kilograms and percentage)\], measured via bioimpedance analysis (InBody 970 model, Biospace, Korea), will be combined to report the complete assessment of body composition.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

  2. Muscle strength

    Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The handgrip strength evaluation method follows the Southampton protocol. Participants perform three trials in each hand (alternating sides), and the maximal grip score will be used. Assessment of isometric knee extensor strength will be performed with participants seated. The test involves three maximal voluntary isometric contractions. Participants will be instructed to hold the side of the plinth for stabilization. Constant verbal encouragement will be provided throughout the testing. A submaximal practice trial is performed for each leg to ensure the participant understands the required contraction. Three trials will be recorded for each knee, and the maximal strength value will be used.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

  3. Cardiorespiratory fitness (CRF)

    The estimated CRF (ml/min/kg) will be evaluated using the 2-minute step test (2MST). Briefly, the 2MST will be performed using a single, portable step that is 15 cm high. Participants are instructed to go up and down the step as many times as possible for two minutes (free cadence). The evaluator is responsible for counting up-and-down step cycles (UDS). The test will be performed according to the recommendations of the American Thoracic Society.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

  4. Identification of proteomic differences in skeletal muscle and visceral adipose tissue associated with adherence at the time of surgery

    Tissue fragments will be immediately processed and preserved at -80 ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups.

    Time frame: Intra-operative: T2

  5. Longitudinal blood metabolomic adaptations

    Plasma will be processed and stored at -80 ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points.

    Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).

07

Study locations

1 of 1 sites recruiting
  • Unidade Local de Saúde de Entre Douro e Vouga
    Santa Maria da Feira, 4520-211, Portugal
    Recruiting
    • Unidade Local de Saúde de Entre Douro e Vouga · Contactgeral@ulsedv.min-saude.pt · +351 256 379 700
    • Marta Guimarães · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2030, 54 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 54 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Jun 23, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Oct 20, 2030
CompletionEst.
Apr 20, 2031
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07663942
Lead sponsor
Hospital de Sao Sebastiao
Collaborators
Universidade Lusófona - Centro Universitário do Porto, Unidade Multidisciplinar de Investigação Biomédica, Universidade do Porto, COFAC Cooperativa de Formacao e Animacao Cultural CRL (Portugal)
Responsible party
Marta Guimarães (MD, PhD; Bariatric Surgeon, Investigator and Assistant Professor, Hospital de Sao Sebastiao) — Principal investigator
First posted
Jun 23, 2026
Start date
Apr 20, 2026
Primary completion
Oct 20, 2030 (estimated)
Completion
Apr 20, 2031 (estimated)
Last update
Jun 23, 2026

Study contacts

Unidade Local de Saúde Entre Douro e Vouga
Contact
geral@ulsedv.min-saude.pt
+351 256 379 700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion